... identified using ICD-10 codes from all primary discharge diagnoses. Only deep venous thrombosis (DVT) and pulmonary embolism (PE) were considered. Patients with VTE were further divided into groups: esophageal cancer, gastric cancer, pancreatic cancer, and colorectal cancer, and compared with patients who...

...Noriyoshi Takahashi; Rei Umezawa; Takaya Yamamoto; Kazuya Takeda; Yu Suzuki; Keita Kishida; So Omata; Yuta Sato; Hinako Harada; Yasuhiro Seki; Keiichi Jingu Introduction: Patients with esophageal cancer who are in a poor general condition receive radiotherapy alone, but outcomes are often...

... in Barrett’s esophagus [ 15-22 ]. The recently proposed Japan Esophageal Society Barrett’s Esophagus (JES-BE) classification is useful in terms of diagnostic accuracy and convenience [ 23-25 ]. The Japanese guidelines for ESD of esophageal cancer recommend image-enhanced magnifying endoscopic examination...

...Ian Torres de Lima; Edno Tales Bianchi; Gabriel Lunardi Aranha; Beatriz Camargo Azevedo; Guilherme Naccache Namur; Jaime Arthur Pirola Kruger Hiatal hernia is a rare postoperative complication of esophagectomy in the treatment of esophageal cancer. Although rare, its incidence increased after...

...Yoshinori Fujiwara; Masaharu Higashida; Hisako Kubota; Yuko Okamoto; Shumei Mineta; Shunji Endo; Tomio Ueno Introduction: We studied whether perioperative nutritional, immunological factors or postoperative inflammatory responses predicted esophageal cancer (EC) progression and prognosis...

.... However, the clinical benefit of IN in patients who have undergone esophagectomy for esophageal cancer is unclear. Moreover, the effect of enteral IN in patients during preoperative adjuvant chemoradiotherapy and in patients treated with concurrent chemoradiotherapy for advanced esophageal cancer...

...Aiwu Mao Esophageal cancer (EC) is the fourth leading cause of cancer death in China. Despite a lot of advances in diagnosis and therapy, the survival rate of patients with EC is low. There is urgent need for a variety of methods and techniques to improve the survival time and alleviate the lesions...

...Romina Barani; Gholamreza Motalleb; Hossein Maghsoudi Background: Esophageal cancer is a public health concern around the world; this cancer is the sixth leading cause of death of cancer in the world with about 386,000 deaths per year. Its risk factors include environmental factors such as tobacco...

...Chung S. Yang; Xiaoxin Chen; Shuiping Tu Background: Esophageal cancer (EC) occurs commonly, especially in Asia, and is the sixth leading cause of cancer deaths worldwide. Recently, great progress has been made in research on the etiology and prevention of EC. Summary: The major risk factors...

...Daniel Reim; Helmut Friess Background: Patients undergoing treatment for esophagogastric or esophageal cancer are exposed to a considerably high risk of malnutrition due to early obstruction of the gastrointestinal passage. Presently most of the patients undergo modern multimodal therapies which...

...Tahereh Salari Fanoodi; Gholamreza Motalleb; Ahmad Yegane Moghadam; Rezvan Talaee Background: Cancer is the third most common cause of death in Iran, and 30,000 Iranians lose their lives each year due to cancer. Esophageal cancer is the eighth most common cancer and the sixth leading cause of death...

...Jin Qian; Jing-Yuan Fang Background: Esophageal cancer is one of the most prevalent cancers worldwide, and occurs at a relatively high frequency in China and other Asian countries. The etiology of esophageal cancer remains unclear, making its early diagnosis and treatment difficult. Summary...

...Wenjia Xu; Zhongshun Liu; Qunchao Bao; Zhikang Qian Background: Esophageal cancer (EC) is the eighth most prevalent malignant tumor and the sixth leading cause of cancer mortality throughout the world. Despite the technical developments in diagnosis and treatment, the 5-year survival rate is still...

...Li Sun; Hongwei Zhang; Kaichun Wu Background: Esophageal cancer (EC) is the eighth most common cancer worldwide. A worldwide-established consensus on therapeutic pathways for EC is still missing. Debate exists on whether neoadjuvant and adjuvant treatment regimens improve the prognosis and which...